glp-1 and dual glp-1/gip receptor agonists GIP/GLP-1 agonists: New advances for treating type-2 diabetes The Sustained Effects of a
Description
Scarce data exist on the outcomes of AP in patients with T2DM who are taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K
part of what tirzepatide adds on top of GLP-1
[DOI] [PubMed] [Google Scholar] 9.Koliaki C., Doupis J
For Canadians comparing research peptide options, this efficacy difference represents the primary advantage of the triple-agonist mechanism
Diabetes Metab Syndr Obes (2020) 13:307587
